Eli Lilly launched an ad campaign on Friday, cautioning patients against the risks of unapproved weight-loss drugs in its ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...

After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...

Coverage complications are not unusual in the U.S. health care system. But the challenge is magnified for these obesity ...

Hims & Hers, which launched a Super Bowl ad touting its weight loss product offerings, markets a compounded version of semaglutide, the active ingredient in Ozempic and Wegovy. Shares of Hims ...

The company promoted its weight-loss offerings in a Super Bowl ad as “affordable” and ... s Mounjaro treat Type 2 diabetes, while Wegovy and Zepbound are anti-obesity medications.

The Super Bowl aired a Hims & Hers commercial that is receiving backlash for its non-FDA approved weight loss drug. This drug ...

Ozempic and Wegovy, the widely popular forms of semaglutide ... its sale of compounded GLP-1 drugs in a 60-second Super Bowl ad earlier this month, drawing some scrutiny and criticisms.

Advertisement Article continues below this ad The injectable ... They use the same active ingredient, tirzepatide. Ozempic, for diabetes, and Wegovy, for weight loss, use the active ingredient ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer ... most under claims of false advertising or deceptive and unfair trade practices. “No one should have to compromise ...